Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908844 | 0.90 | S1PR2 (0.61) | S1PR2KCNH2AKR1B1ALOX15 | |
| SCHEMBL23915067 | 0.86 | S1PR2 (0.52) | S1PR2KCNH2MAPTPOLBALDH1A1 | |
| SCHEMBL23908771 | 0.84 | S1PR2 (0.50) | S1PR2KCNH2 | |
| SCHEMBL23908999 | 0.83 | S1PR2 (0.54) | S1PR2KCNH2MAPTMAPK1LMNA | |
| SCHEMBL23909002 | 0.82 | S1PR2 (0.49) | S1PR2KCNH2 | |
| SCHEMBL23908879 | 0.82 | S1PR2 (0.49) | S1PR2KCNH2 | |
| SCHEMBL23909158 | 0.77 | S1PR2 (0.64) | S1PR2KCNH2AKR1B1ALOX15KMT2A | |
| SCHEMBL23908869 | 0.77 | S1PR2 (0.79) | S1PR2KCNH2AKR1B1ALOX15 | |
| SCHEMBL23908841 | 0.77 | S1PR2 (0.79) | S1PR2KCNH2ALOX15 | |
| SCHEMBL23966899 | 0.74 | S1PR2 (0.81) | S1PR2KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |